
Opinion|Videos|September 6, 2024
Addressing Unmet Needs and Emerging Agents
Jonathan Silverberg, MD, PhD, MPH, evaluates persistent unmet needs in the field and highlights promising new treatments currently under development.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Despite the available treatment options, what are the remaining unmet needs or areas requiring further research and development in the management of disease states driven by type 2 inflammation?
- What emerging agents in the pipeline are you most excited for?
Advertisement
Related to this article

CRC diagnoses after endoscopic mucosal resection (EMR) were uncommon in a real-world cohort, though racial and ethnic differences remain unclear.

San Francisco experts say earlier IgA nephropathy and FSGS detection depends on primary care education and care coordinators.

The FDA has approved secukinumab for PMR after the REPLENISH trial showed doubled sustained remission and lower steroid use vs a steroid taper alone.

Earlier MASH fibrosis detection is more urgent now that treatments exist, and automating FIB-4 in EHRs could help primary care, says Rohit Loomba, MD.

In this Q&A, Jesús Corral Jaime, MD, discusses real-world CEMI-LUNG data on cemiplimab in advanced NSCLC presented at the ESMO 2026 Congress.

Neladalkib earned accelerated approval for previously treated ALK-positive NSCLC, with ORRs of 49% and 32%.
Advertisement
Advertisement



